Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Invested Capital (2020 - 2023)

Historic Invested Capital for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $258.4 million.

  • Terns Pharmaceuticals' Invested Capital rose 4068.23% to $258.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $258.4 million, marking a year-over-year increase of 4068.23%. This contributed to the annual value of $276.9 million for FY2022, which is 7276.22% up from last year.
  • As of Q3 2023, Terns Pharmaceuticals' Invested Capital stood at $258.4 million, which was up 4068.23% from $274.2 million recorded in Q2 2023.
  • Terns Pharmaceuticals' 5-year Invested Capital high stood at $287.7 million for Q1 2023, and its period low was -$119.8 million during Q3 2020.
  • Over the past 4 years, Terns Pharmaceuticals' median Invested Capital value was $172.2 million (recorded in 2021), while the average stood at $122.5 million.
  • As far as peak fluctuations go, Terns Pharmaceuticals' Invested Capital skyrocketed by 29050.68% in 2021, and later tumbled by 2432.89% in 2022.
  • Quarter analysis of 4 years shows Terns Pharmaceuticals' Invested Capital stood at -$104.6 million in 2020, then soared by 253.31% to $160.3 million in 2021, then surged by 72.76% to $276.9 million in 2022, then decreased by 6.69% to $258.4 million in 2023.
  • Its last three reported values are $258.4 million in Q3 2023, $274.2 million for Q2 2023, and $287.7 million during Q1 2023.